http://www.washingtonpost.com/wp-dyn/articles/A60149-2002May22.html
QUOTE: Bill to Boost Industry Fees That Fund FDA Critics Fear Conflicts By Marc Kaufman Washington Post Staff Writer Thursday, May 23, 2002; Page A01 With little public discussion and limited debate on Capitol Hill, Congress is moving to substantially expand the program through which companies pay large fees to the Food and Drug Administration to review their new drug applications -- making the agency increasingly dependent on the businesses that it regulates. END QUOTE
